 Biophytis SA NASDAQ: BPTS said that it is currently assessing FDA comments and recommendations and preparing to submit Phase 2-3 trial designs for sarconeos BIO101 trial in sarcopenia. Enrollment is expected to start in 2H of 2022 in the SARA Phase 2 trial. 